This category covers biotechnology and pharmaceutical companies developing therapeutics that target glucocerebrosidase (GBA) for Parkinson's disease treatment. GBA mutations represent the most common genetic risk factor for PD, increasing risk 5-20x and accounting for approximately 5-10% of all PD cases["@sidransky2009"]. The therapeutic approaches listed here aim to restore GBA enzyme function, reduce toxic substrate accumulation, or address the downstream effects of GBA dysfunction on alpha-synuclein pathology["@mazzulli2011"].
Key Companies
Gene Therapy Approaches
Gene therapy aims to deliver a functional GBA1 gene to restore glucocerebrosidase activity in the central nervous system. This approach offers potential for long-term disease modification.
Prevail Therapeutics (Eli Lilly)
Focus: AAV-GBA1 gene therapy for PD patients with GBA1 mutations
Lead Candidate: PR001
Indication: Parkinson's disease with GBA1 mutations
Stage: Phase 1/2 (PROVIEW trial)
Mechanism: AAV9-mediated delivery of functional GBA1 gene via intrathecal administration
Status: Acquired by Eli Lilly in 2021 for $880 million
Indication: Parkinson's disease with GBA1 mutations
Stage: Phase 1
Mechanism: Next-generation AAVhu68 capsid for enhanced CNS delivery via intra-cisterna magna administration
Page: [Passage Bio](/companies/passage-bio)
uniQure
Focus: AAV-GBA gene therapy
Lead Candidate: AMT-260 (formerly)
Indication: Parkinson's disease, GBA-associated
Stage: Phase 1
Mechanism: AAV-based gene delivery of functional GBA1
Page: [uniQure](/companies/uniqure)
Molecular Chaperone Therapy
Molecular chaperones are small molecules that stabilize mutant GBA enzymes, improving their folding, trafficking, and enzymatic activity. This approach can restore partial enzyme function.
Gain Therapeutics
Focus: Small molecule GBA modulators (therapeutic chaperones)
[ClinicalTrials.gov - GBA Parkinson's](https://clinicaltrials.gov/search?cond=Parkinson%27s+disease&intr=GBA)
Pathway Diagram
The following diagram shows the key molecular relationships involving PD GBA Glucocerebrosidase Therapeutic Companies discovered through SciDEX knowledge graph analysis: